See the DrugPatentWatch profile for Vumerity
Vumerity, an oral medication approved for treating relapsing forms of multiple sclerosis (MS), does not currently have a generic version available [1]. The drug is manufactured by Biogen [2].
When will Vumerity go generic?
The patent exclusivity for Vumerity has not yet expired, which is why a generic version is not available. Drug patent information, including expiry dates, can be tracked on resources like DrugPatentWatch.com [1].
What is the difference between Vumerity and other MS treatments?
Vumerity (diroximel fumarate) is a fumaric acid ester with a distinct chemical structure compared to other fumarate treatments like Tecfidera (dimethyl fumarate) [3]. This difference is intended to reduce gastrointestinal and flushing side effects experienced by some patients taking older fumarate therapies [3]. Vumerity is taken orally, unlike some injectable or infusible MS medications [1].
Why aren't generic drugs always available immediately?
Generic drug availability is contingent on the expiration of patents held by the original drug manufacturer. These patents grant exclusive marketing rights for a specified period. Once patents expire, other companies can seek approval from regulatory bodies to market their own generic versions of the drug, provided they demonstrate bioequivalence [4].
What is the active ingredient in Vumerity?
The active ingredient in Vumerity is diroximel fumarate [3].